Low levels of a single enzyme influence pathway to malignancy in colorectal cancer, scientists find
The transformation of healthy cells into invasive colorectal tumors is an extraordinarily complex process involving numerous ...
Novel Alzheimer's drug candidate reduces inflammation and protects neurons
Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited ...
Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE 515
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune ...
Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients
Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of ...
News-Medical.Net on MSN16h
New drug shows neuroprotective and anti-inflammatory effects in murine models of Alzheimer's
Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited efficacy and only in mild stages of the disease.
Arialief Reviews & Complaints (ALERT): Is This Nerve Pain Breakthrough Too Good To Be Real?
Nerve damage isn’t just about pain—it’s about decay. Arialief includes Alpha Lipoic Acid (ALA) because it does what few ...
PharmiWeb20h
Jabez Biosciences, Inc. Announces First Patient Dosed in Phase 1 Oncology Clinical Study of JBZ-001
ZIONSVILLE, INDIANA / ACCESS Newswire / April 2, 2025 / Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in the future of cancer therapy, today announced that ...
News-Medical.Net on MSN3d
Traditional Chinese medicine targets cholesterol metabolism for cancer treatment
Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat ...
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.